These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7723892)

  • 1. Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome.
    Hong SY; Yang DH
    Nephron; 1995; 69(2):125-30. PubMed ID: 7723892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
    Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
    J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting fibrinolytic potential: cardiovascular fitness, body composition, and lipoprotein(a).
    Szymanski LM; Durstine JL; Davis PG; Dowda M; Pate RR
    Metabolism; 1996 Nov; 45(11):1427-33. PubMed ID: 8931650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome.
    Wanner C; Rader D; Bartens W; Krämer J; Brewer HB; Schollmeyer P; Wieland H
    Ann Intern Med; 1993 Aug; 119(4):263-9. PubMed ID: 8328733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients.
    Vucković BA; Djerić MJ; Ilić TA; Canak VB; Kojić-Damjanov SLj; Zarkov MG; Cabarkapa VS
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():12-7. PubMed ID: 20229676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated lipoprotein (a) levels in primary nephrotic syndrome.
    Faucher C; Doucet C; Baumelou A; Chapman J; Jacobs C; Thillet J
    Am J Kidney Dis; 1993 Dec; 22(6):808-13. PubMed ID: 8250027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolytic parameters and lipoprotein(a) in young women with myocardial infarction.
    Salobir B; Sabovic M; Peternel P; Stegnar M
    Angiology; 2002; 53(2):157-63. PubMed ID: 11952105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease.
    Orem A; Değer O; Memiş O; Bahadir S; Ovali E; Cimşit G
    Ann Rheum Dis; 1995 Sep; 54(9):726-9. PubMed ID: 7495343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease.
    Suefuji H; Ogawa H; Yasue H; Imoto N; Sakamoto T; Miyao Y; Kaikita K; Soejima H; Nishiyama K
    Coron Artery Dis; 1996 Feb; 7(2):167-72. PubMed ID: 8813450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome.
    Noto D; Barbagallo CM; Cascio AL; Cefalù AB; Cavera G; Caldarella R; Marino G; Travali S; Cutaia I; Maringhini S; Notarbartolo A; Averna M
    Kidney Int; 1999 Jun; 55(6):2433-9. PubMed ID: 10354292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Euglobulin clot lysis induced by tissue-type plasminogen activator is reduced in subjects with increased levels of lipoprotein (a).
    Aznar J; Estellés A; Bretó M; España F; Alós T
    Thromb Res; 1992 Jun; 66(5):569-82. PubMed ID: 1387993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a) levels in the nephrotic syndrome.
    Kanno H; Saito E; Fujioka T; Yasugi T
    Intern Med; 1992 Aug; 31(8):1004-8. PubMed ID: 1477459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein(a) in patients with the nephrotic syndrome: influence of immunosuppression and proteinuria.
    Wanner C; Bartens W; Nauck M; Zäuner I; Greiber S; Schollmeyer P
    Miner Electrolyte Metab; 1996; 22(1-3):26-30. PubMed ID: 8676820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fibrinolytic and lipid disturbances in patients with nephrotic syndrome].
    Małyszko J; Małyszko JS; Mysliwiec M
    Pol Arch Med Wewn; 1994 Nov; 92(5):394-9. PubMed ID: 7885987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasma Lp (a) levels and correlation of Lp (a) with fibrinolysis activation in chronic renal failure].
    Zhu J; Xiong X; Zhao S; Wang Z; Lou L; Hang Q
    Hunan Yi Ke Da Xue Xue Bao; 1999; 24(4):366-8. PubMed ID: 12080650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of cardiorespiratory fitness to inflammatory markers, fibrinolytic factors, and lipoprotein(a) in patients with type 2 diabetes mellitus.
    Jae SY; Heffernan KS; Lee MK; Fernhall B; Park WH
    Am J Cardiol; 2008 Sep; 102(6):700-3. PubMed ID: 18773991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome.
    Hu P; Lu L; Hu B; Du PF
    Scand J Clin Lab Invest; 2009; 69(6):680-6. PubMed ID: 19468931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma lipoprotein(a) levels and fibrinolytic activity in patients with unstable angina.
    Okubo H; Yasue H; Ogawa H; Misumi I; Masuda T; Miyao Y; Sakamoto T
    Jpn Circ J; 1993 Oct; 57(10):947-54. PubMed ID: 7901435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria.
    Gansevoort RT; Heeg JE; Dikkeschei FD; de Zeeuw D; de Jong PE; Dullaart RP
    Nephrol Dial Transplant; 1994; 9(3):244-50. PubMed ID: 8052429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome.
    Brown CD; Azrolan N; Thomas L; Roberts KG; Bostom A; Zhao ZH; Friedman EA
    Am J Kidney Dis; 1995 Jul; 26(1):170-7. PubMed ID: 7611249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.